ChemBridge Corporation announced a new multi-year research collaboration in discovery chemistry with AstraZeneca. This new alliance follows the previous collaboration between ChemBridge and AstraZeneca that was established in 2006 and successfully completed earlier this year ahead of schedule.
In accordance with the new agreement scientists from ChemBridge and AstraZeneca will work together to design and develop a new generation of highly advanced, research intensive small molecule libraries that further enhance AstraZeneca's global drug discovery effort. Further details and financial terms were not disclosed.
"We are very pleased to enhance and extend our strategic relationship with AstraZeneca, one of the world's leading pharmaceutical companies, and to continue to build upon our track record of successful teamwork with AstraZeneca," said Eugene Vaisberg, chairman and CEO of ChemBridge Corporation and ChemBridge Research Laboratories, Inc (CRL). "This major new deal, which is focused on the most challenging custom compound libraries, is further proof of ChemBridge's capabilities to succeed in the increasingly competitive global discovery chemistry outsourcing market by targeting its high-end segment and leveraging the skills, expertise and experience of ChemBridge's scientists."
Tony Wilkinson, vice president, Lead Generation DECS, AstraZeneca added, "The success of our previous collaboration demonstrated the capabilities ChemBridge and CRL have in drug discovery chemistry and library synthesis. With our new alliance we are confident that this more challenging project will be executed with similar success."
ChemBridge Corporation is leading global discovery chemistry CRO and screening compound library provider with an impeccable 15 year track record of quality and deliverability.
AstraZeneca is a major international healthcare business engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and supplier for healthcare services.